Tahmina Nasrin Poly1,2,3, Md Mohaimenul Islam1,2,3, Bruno Andreas Walther4, Hsuan-Chia Yang1,2,3, Chieh-Chen Wu1, Ming-Chin Lin1,5, Yu-Chuan Li6,7,8,9,10. 1. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. 2. International Center for Health Information Technology, Taipei Medical University, Taipei, Taiwan. 3. Research Center of Big Data and Meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 4. Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan. 5. Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan. 6. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, jaak88@gmail.com. 7. International Center for Health Information Technology, Taipei Medical University, Taipei, Taiwan, jaak88@gmail.com. 8. Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan, jaak88@gmail.com. 9. TMU Research Center of Cancer Translational Medicine, Taipei, Taiwan, jaak88@gmail.com. 10. Research Center of Big Data and Meta-analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, jaak88@gmail.com.
Abstract
BACKGROUND AND AIMS: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. METHODS: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. RESULTS: A total of 30 observational studies, including 9,162,509 participants (84,101 dementia patients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95% CI 0.79-0.87, I2 = 57.73%). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95% CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95% CI 0.74-1.16, p = 0.54). CONCLUSION: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.
BACKGROUND AND AIMS: The impact of statin on dementia risk reduction has been a subject of debate over the last decade, but the evidence remains inconclusive. Therefore, we performed a meta-analysis of relevant observational studies to quantify the magnitude of the association between statin therapy and the risk of dementia. METHODS: We systematically searched for relevant studies published from January 2000 to March 2018 using EMBASE, Google, Google Scholar, PubMed, Scopus, and Web of Science. Two authors performed study selection, data abstraction, and risk of bias assessment. We then extracted data from the selected studies and performed meta-analysis of observational studies using a random-effects model. Subgroup and sensitivity analyses were also conducted. RESULTS: A total of 30 observational studies, including 9,162,509 participants (84,101 dementiapatients), met the eligibility criteria. Patients with statin had a lower all-caused dementia risk than those without statin (risk ratio [RR] 0.83, 95% CI 0.79-0.87, I2 = 57.73%). The overall pooled reduction of Alzheimer disease in patients with statin use was RR 0.69 (95% CI 0.60-0.80, p < 0.0001), and the overall pooled RR of statin use and vascular dementia risk was RR 0.93 (95% CI 0.74-1.16, p = 0.54). CONCLUSION: This study suggests that the use of statin is significantly associated with a decreased risk of dementia. Future studies measuring such outcomes would provide useful information to patients, clinicians, and policymakers. Until further evidence is established, clinicians need to make sure that statin use should remain restricted to the treatment of cardiovascular disease.
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Nathalie Sumien; J Thomas Cunningham; Delaney L Davis; Rachel Engelland; Oluwadarasimi Fadeyibi; George E Farmer; Steve Mabry; Paapa Mensah-Kane; Oanh T P Trinh; Philip H Vann; E Nicole Wilson; Rebecca L Cunningham Journal: Endocrinology Date: 2021-11-01 Impact factor: 5.051
Authors: Adina Zeki Al Hazzouri; Neal Jawadekar; Leslie Grasset; Paulina Kaiser; Katrina Kezios; Sebastian Calonico; Maria Glymour; Calvin Hirsch; Alice M Arnold; Ravi Varadhan; Michelle C Odden Journal: J Gerontol A Biol Sci Med Sci Date: 2022-05-05 Impact factor: 6.591
Authors: Fardin Nabizadeh; Mohammad Balabandian; Amir Mohammad Sharafi; Ali Ghaderi; Mohammad Reza Rostami; Abdorreza Naser Moghadasi Journal: Acta Neurol Belg Date: 2021-07-28 Impact factor: 2.471